GlassScriptPhysician profile
Mohammad A Quasem
NPI 1578559399
$1,976.66
in general payments reported to CMS, 2019-2025
17 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $337 · 2022: $119 · 2023: $252 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $410.40 | 2019-2023 | |
| Vifor Pharma, INC. | $359.16 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $190.24 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $157.69 | 2019 | |
| Travere Therapeutics, INC. | $125.00 | 2025 | Filspari |
| Veloxis Pharmaceuticals, INC. | $124.25 | 2020 | |
| Horizon Therapeutics Plc | $116.64 | 2023 | Krystexxa |
| Akebia Therapeutics INC | $115.23 | 2019 | |
| Fresenius USA Marketing, INC. | $103.12 | 2019-2025 | Velphoro |
| Baxter Healthcare | $67.82 | 2020 | |
| Mallinckrodt Hospital Products INC. | $39.93 | 2020 | |
| Shire North American Group INC | $38.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.33 | 2019 | |
| Daiichi Sankyo INC. | $33.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $25.70 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.39 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.27 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Quasem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.